As of December 31, 2022, Sol-Gel had $24.9M in cash, cash equivalents and bank deposits, and $8.7 million in marketable securities for a total balance of $33.6M. Following the $22.8M raised in the recent financing, the Company expects that its cash resources will enable funding of operational and capital expenditure requirements into the second half of 2025.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SLGL:
- Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments
- Sol-Gel announces $22.8M registered direct, private placement offerings
- Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
- Sol-Gel Technologies acquires Phase 3 Gorlin syndrome candidate patidegib
- Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
